Damora Therapeutics
DMRA · NASDAQ
$20.67+$1.40 (+7.27%)TodayMarket closed ·
Prev close $19.27
Who owns DMRA
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 64.3% of DMRA’s shares.
- Fidelity Management & Research Company LLC14.9%
- Fairmount Funds Management LLC14.2%
- Avoro Capital Advisors LLC6.1%
- VR Adviser, LLC5.9%
- Next 6 largest institutions23.3%
- All other shareholders35.7%
| Holder | Shares | % of shares |
|---|---|---|
| Fidelity Management & Research Company LLC | 9.15M | 14.87% |
| Fairmount Funds Management LLC | 8.71M | 14.16% |
| Avoro Capital Advisors LLC | 3.78M | 6.15% |
| VR Adviser, LLC | 3.60M | 5.85% |
| BlackRock Institutional Trust Company, N.A. | 2.84M | 4.61% |
| Forbion Capital Partners | 2.44M | 3.97% |
| RA Capital Management, LP | 2.40M | 3.90% |
| Viking Global Investors LP | 2.31M | 3.75% |
| Janus Henderson Investors | 2.28M | 3.71% |
| Remedium Capital Partners, LLC | 2.05M | 3.32% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Fidelity Growth Company Fund | 1.83M | 2.97% |
| iShares Russell 2000 ETF | 1.36M | 2.21% |
| Fidelity Small Cap Growth Fund | 834.04K | 1.36% |
| State Street SPDR S&P Biotech ETF | 754.42K | 1.23% |
| JPMorgan Small Cap Growth Fund | 731.21K | 1.19% |
Insider trades
Form 4 filings by officers, directors and large holders
Over the last 6 months, insiders bought $252.87K (1 trade) and sold $7.35K (1 trade) of DMRA on the open market.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Jarrett Jennifer | Buy | 12.50K | $252.87K |
| Cheng Andrew | Award | 30.35K | — |
| Winslow Garrett | Sale | 245 | $7.35K |
| Winslow Garrett | Option exercise | 680 | — |
| Winslow Garrett | Option exercise | 680 | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 4.73M
- Days to cover
- 4.80
- % of shares outstanding
- 7.69%
- Average daily volume
- 985.49K
- Change since last report
- +0.0%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.